Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Clinical Trial on the Efficacy and Safety of RC48-ADC (Disitamab Vedotin) Combined With Toripalimab in Advanced HER2-positive Extramammary Paget Disease of the Scrotum

NCT06791070 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT06791070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06791070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Clinical Trial on the Efficacy and Safety of RC48-ADC (Disitamab Vedotin) Combined With Toripalimab in Advanced HER2-positive Extramammary Paget Disease of the Scrotum
Lead sponsor
Fujian Medical University Union Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 31, 2025
Completion date
January 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paget disease, extramammary, scrotum disease